Streetbeat News

Price Targets

LANC

Stephens & Co. analyst Jim Salera downgraded Lancaster Colony (LANC) from Overweight to Equal-Weight but raised the price target from $205 to $218.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 12:30 pm

NRIX

Needham analyst Gil Blum reiterated a Buy rating on Nurix Therapeutics (NASDAQ:NRIX) and maintained a $31 price target.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 12:27 pm

MCHP

Needham analyst Quinn Bolton maintains a Buy rating on Microchip Technology (NASDAQ:MCHP) and raises the price target from $85 to $90.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 12:25 pm

CLFD

Needham analyst Ryan Koontz maintains a Buy rating on Clearfield (NASDAQ:CLFD) but lowers the price target from $40 to $36.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 12:22 pm

AMZN

JP Morgan analyst Doug Anmuth maintains an Overweight rating on Amazon.com (NASDAQ:AMZN) and raises the price target from $190 to $225, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 12:18 pm

AAPL

Needham analyst Laura Martin reiterates a Buy rating on Apple (AAPL) and maintains a $220 price target.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 12:15 pm

AMZN

Needham analyst Laura Martin maintains a Buy rating on Amazon.com (NASDAQ:AMZN) and raises the price target from $175 to $205.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 12:14 pm

CATX

EXFY

PCSA

RVP

Insiders are buying shares in four US-listed companies under $3: Retractable Technologies, Expensify, Perspective Therapeutics, and Processa Pharmaceuticals. These transactions indicate insider confidence in the companies' prospects. Retractable Technologies reported a loss, while Expensify received a price target upgrade. Perspective Therapeutics signed a licensing agreement, and Processa Pharmaceuticals announced a public offering.

Portfolio Pulse from Avi Kapoor

February 02, 2024 | 12:09 pm

BYON

Needham analyst Anna Andreeva has reiterated a Buy rating on Beyond (NYSE:BYON) and maintained a $40 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 12:08 pm

COUR

Needham analyst Ryan MacDonald has maintained a Buy rating on Coursera (NYSE:COUR) and increased the price target from $21 to $23.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 12:02 pm